JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(2):103-107 | DOI: 10.36290/csf.2025.014

CAR-T therapy - the role of the pharmacist

Marcela Heislerová
Nemocniční lékárna, Fakultní nemocnice v Motole, Praha
IPVZ, Praha

CAR-T therapy uses and advances the ability of the human immune system to attack tumor cells. It can currently only be administered in specialized treatment centers in the Czech Republic, which must be able to ensure the collection of T lymphocytes, their sending for preparation, the subsequent administration of CAR-T preparations, as well as the recognition, monitoring and management of possible adverse effects of the treatment (1). The aim of this article is to highlight the role of hospital pharmacists, who are key to the correct handling of these highly specialized preparations. Due to the difficulty of handling and the high price of these preparations, it is necessary to have all steps standardized and documented. Hospital pharmacists are guarantors of the correct handling of all medicinal products in hospitals and play an important role in the management of CAR-T therapies. They actively participates not only in providing CAR-T preparations for medical facilities, but also in solving irregularities and defects connected with their application. Patient care is complex and is based on the multidisciplinary cooperation of health professionals, in which hospital pharmacists also have their place.

Keywords: CAR-T therapy, hospital pharmacist, medication management.

Accepted: May 28, 2025; Published: June 18, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heislerová M. CAR-T therapy - the role of the pharmacist. Čes. slov. farm. 2025;74(2):103-107. doi: 10.36290/csf.2025.014.
Download citation
PDF will be unlocked 18.6.2026

References

  1. Doporučený postup České hematologické společnosti ČLS JEP, Buněčná terapie - T-lymfocyty s chimérickým antigenním receptorem (CAR-T). In: Hematology.cz [www.hematology.cz] 2023 Apr 20. [cited 2025 Jan 25]. Available from: https://www.hematology.cz/wp-content/uploads/2023/04/20-Bunecna_terapie-CAR-T-verze-02-2023.pdf.
  2. Belada D, Trněný M, et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy - XIV. Vydání. In: Lymphoma.cz [www.lymphoma.cz] 2024 March. [cited 2025 Jan 25]. Available from: https://www.lymphoma.cz/_uploads/attachments/KLS_guidelines_2024_final.pdf.
  3. EAHP Position Paper on Advanced Therapy Medicinal Products. In: EAHP.cz [www.eahp.eu] 2024 March. [cited 2025 Jan 25]. Available from: https://eahp.eu/wp-content/uploads/2024/03/eahp_position_paper_on_advanced_therapy_medicinal_products.pdf
  4. Lysák D. Imunoterapie pomocí CAR T-lymfocytů. Onkologie. 2015;9(1):13-18.
  5. Zákon č. 378/2007 Sb., Zákon o léčivech a o změnách některých souvisejících zákonů (zákon o léčivech) ve znění pozdějších předpisů.
  6. Červená kniha České hematologické společnosti ČLS JEP. In: Hematology.cz [www.hematology.cz] 2024 April 4. [cited 2025 Jan 25]. Available from: https://www.hematology.cz/wp-content/uploads/2023/04/20-Bunecna_terapie-CAR-T-verze-02-2023.pdf.
  7. Zákon č. 136/2017Sb. (Zákon, kterým se mění zákon č. 296/2008 Sb., o zajištění jakosti a bezpečnosti lidských tkání a buněk určených k použití u člověka a o změně souvisejících zákonů /zákon o lidských tkáních a buňkách/, ve znění pozdějších předpisů).
  8. Výbor Sekce nemocniční farmacie ČFS ČLS JEP. Nemocniční farmacie - farmaceutická péče a medikační management ve zdravotnickém zařízení lůžkové péče (oborová koncepce). In: Nemfarm.cz. [https://nemfarm.cz ] 2022 Nov 12. [cited 2025 Jan 25]. Available from: https://nemfarm.cz/o-nas/koncepce-oboru/.
  9. The European Statements of Hospital Pharmacy. Eur J Hosp Pharm 2014;21:256-8. Go to original source...
  10. Zákon č. 541/2020 Sb., o odpadech ve znění pozdějších předpisů.
  11. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions, Pharmaceutical Strategy for Europe, COM(2020) 761 final. [cited 2024 Dec 29] Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:52020DC0761.
  12. European Medicines Agency, EMA Regulatory Science to 2025 Strategic reflection. In: Ema.europa. [www.ema.europa.eu eu]. 2020 Mar 31 [cited 2024 Dec 29 ]. Available at: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf.
  13. Beková L. CAR - T terapie a úloha farmaceuta v procesech zajištění léčivého přípravku [atestační práce]. IPVZ, Praha; 2022.
  14. Kröger N. The EBMT/EHA CAR-T Cell Handbook. New York City: Springer; 2022. Go to original source...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.